A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

INTRODUCTION: The Understanding New Interventions with GBM ThErapy (UNITE) study was designed to assess the effect of prophylaxis for ocular side effects (OSEs) in patients with glioblastoma receiving the antibody-drug conjugate (ADC) depatuxizumab mafodotin. UNITE (NCT03419403) was a phase 3b, open...

Descripción completa

Detalles Bibliográficos
Autores principales: Vize, Colin J., Kim, Stella K., Matthews, Tim, Macsai, Marian, Merrell, Ryan, Hsu, Sigmund, Kundu, Madan Gopal, Yoon, Jennifer, Kennedy, Emma, Pai, Madhavi, Bain, Earle, Lassman, Andrew B., Moazami, Golnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413800/
https://www.ncbi.nlm.nih.gov/pubmed/37257422
http://dx.doi.org/10.1159/000531142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413800/
https://www.ncbi.nlm.nih.gov/pubmed/37257422
http://dx.doi.org/10.1159/000531142

Ejemplares similares